The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal

Abstract Background Erenumab, a fully human monoclonal antibody directed against the calcitonin gene-related peptide receptor, was approved for the prevention of episodic (EM) or chronic migraine (CM) at the monthly dose of 70 mg or 140 mg. We reviewed the available literature to understand if patie...

Full description

Bibliographic Details
Published in:The Journal of Headache and Pain
Main Authors: Raffaele Ornello, Cindy Tiseo, Ilaria Frattale, Giulia Perrotta, Carmine Marini, Francesca Pistoia, Simona Sacco
Format: Article
Language:English
Published: BMC 2019-10-01
Subjects:
Migraine
Calcitonin gene-related peptide
Migraine prevention
Monoclonal antibodies
Erenumab
Online Access:http://link.springer.com/article/10.1186/s10194-019-1054-4

Internet

http://link.springer.com/article/10.1186/s10194-019-1054-4

Similar Items